Biocon partners with Voluntis to develop digital therapeutics for diabetes patients

The licensing agreement, signed between Biocon Biologics’ subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis, would make Biocon Biologics one of the first insulin companies to offer a US Food and Drug Administration-cleared and CE-marked, digital therapeutic product - Insulia - to Type 2 diabetes patients, said Biocon in a press release.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2WIfGfD
via IFTTT